Search

Showing total 1,860 results

Search Constraints

Start Over You searched for: Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years Publication Type Academic Journals Remove constraint Publication Type: Academic Journals Publication Type Trade Publications Remove constraint Publication Type: Trade Publications Journal alimentary pharmacology & therapeutics Remove constraint Journal: alimentary pharmacology & therapeutics Publisher wiley-blackwell Remove constraint Publisher: wiley-blackwell
1,860 results

Search Results

1. Monitoring disease progression in metabolic dysfunction‐associated steatotic liver disease.

2. Systematic review: Clinical phenotypes, histopathological features and prognosis of enteropathy due to angiotensin II receptor blockers.

3. Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients—Authors' reply.

4. Editorial: Hepatitis C virus eradication improves skeletal muscle mass—Authors' reply.

5. Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma.

7. Practical considerations for fluid resuscitation in cirrhosis.

17. Editorial: ARFI‐based techniques are better than VCTE for diagnosing advanced fibrosis in severe obesity—Authors' reply.

25. Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply.

26. Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease—Authors' reply.

27. Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease.

28. Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply.

31. Editorial: Has MetALD met the presumption? Authors' reply.

34. Editorial: Has MetALD met the presumption?

35. Editorial: Another brick in the CDST wall.

37. Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply.

40. Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD.

42. Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood—Authors' reply.

44. Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis.

45. Letter: The enigma of angiotensin receptor blocker‐associated enteropathy—Authors' reply.

48. Letter: The enigma of angiotensin receptor blocker‐associated enteropathy.

49. Editorial: High qHBsAg—is it a good or bad signal?